Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sub-Standard Meds Flood Afghan Market

By Drug Discovery Trends Editor | November 19, 2014

Half of all medicine available on the Afghan market has either been smuggled into the country or made under sub-standard conditions in neighboring Pakistan, according to a report released on Wednesday.

Up to 300 companies in Pakistan produce poor quality drugs exclusively for Afghanistan because their products do not meet Pakistani government standards, said the report by the Independent Joint Anti-Corruption Monitoring and Evaluation Committee, a joint body set up by the Afghan government and international community.

Since there is no Afghan government regulation of pharmaceuticals, the medicine can be sold freely in Afghanistan, it said.

“The market for imported pharmaceuticals here is between $700 million and 800 million, and more than half of it is illicitly imported drugs,” said Eva Joly, the head of the committee. Joly called on the Afghan government to begin regulating the pharmaceutical market.

This flood of poor quality drugs causes wider health problems for the Afghan people; in addition to ineffective treatment of illnesses, the substandard drugs often cause dangerous side-effects. The poor standard of local drugs and healthcare forces many Afghans who can afford it to travel abroad for medical treatment.

Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50